Creating virtuous cycles in drug development with Rob Freishtat

Transformation in Trials

Send us a text

Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.
• Current market uncertainty and investment challenges in biotech, especially for rare disease research
• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
• Companies often treat development phases as "islands" rather than planning for commercial success from the beginning
• Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations
• Reviving shelved drug candidates represents a potentially valuable opportunity
• Patients should have greater input in trial design and outcome measures that matter to them
• Better communication between sponsors and regulators could significantly improve drug development
Support the show

________
Reach out to Ivanna Rosendal
Join the conversation on our LinkedIn page

Kapitel

1. Creating virtuous cycles in drug development with Rob Freishtat (00:00:00)

2. Introduction to Transformation in Trials (00:00:19)

3. Current Market Dynamics in Biotech (00:01:45)

4. Streamlining Drug Development Processes (00:08:22)

5. Planning for Success in Drug Development (00:13:39)

6. The Economics of Rare Disease Drugs (00:22:31)

7. Improving Communication with Regulators (00:37:51)